|1. TYPE OF DRUG- Cefotaxime|
|Cefotaxime (INN) is a third-generation cephalosporin antibiotic.
|2. INDICATIONS (USE)- Cefotaxime|
|Used to treat gonorrhoea, meningitis, and severe infections including infections of the kidney (pyelonephritis) and urinary system. Also used before an operation to prevent infection after surgery.
|3. MECHANISM OF ACTION (MOA)- Cefotaxime|
|The bactericidal activity of cefotaxime results from the inhibition of cell wall synthesis via affinity for penicillin-binding proteins (PBPs). Cefotaxime shows high affinity for penicillin-binding proteins in the cell wall including PBP Ib and PBP III.
|4. ROUTES OF ADMINISTRATION- Cefotaxime|
|5. ONSET OF EFFECT OR ACTION- Cefotaxime|
|6. DOSAGE (DOSING INFORMATION)- Cefotaxime|
0.5 g IM once
Men: 1 g IM once
Women: 0.5 g IM once
Infections Caused by Susceptible Organisms
Uncomplicated: 1 g IV or IM q12hr
Moderate to severe: 1-2 g IV or IM q8hr
More serious (bloodstream infection [septicemia]): 2 g IV q6-8hr
Life-threatening: 2 g IV q4hr; not to exceed 12 g/day
Preparation for Surgery
Prophylaxis of surgical infection
1 g IM/IV once 30-90 minutes before start of procedure
Usual dosage range in children
0-1 week: 50 mg/kg IV q12hr
1-4 weeks: 50 mg/kg IV q8hr
1 month-12 years: 50-180 mg/kg/day IV divided q4-6hr
>12 years: 1-2 g IV/IM q4-8hr
|7. HALF LIFE (DURATION OF ACTION)- Cefotaxime|
|8. ADVERSE EFFECTS OR SIDE EFFECTS – Cefotaxime|
|9. CONTRAINDICATIONS – Cefotaxime|
|Hypersensitivity to cephalosporins.
|10. DRUG INTERACTIONS – Cefotaxime|
|Probenecid decreases cefotaxime elimination.
Potentially Fatal: Nephrotoxicity with furosemide and aminoglycosides.
|11. EXCRETION- Cefotaxime|
|Approximately 20-36% of an intravenously administered dose of 14C-cefotaxime is excreted by the kidney as unchanged cefotaxime and 15-25% as the desacetyl derivative, the major metabolite.